These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 1444502)

  • 1. Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy.
    Edwards L; Berman B; Rapini RP; Whiting DA; Tyring S; Greenway HT; Eyre SP; Tanner DJ; Taylor EL; Peets E
    Arch Dermatol; 1992 Nov; 128(11):1486-9. PubMed ID: 1444502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas.
    Edwards L; Tucker SB; Perednia D; Smiles KA; Taylor EL; Tanner DJ; Peets E
    Arch Dermatol; 1990 Aug; 126(8):1029-32. PubMed ID: 2383027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma.
    Chimenti S; Peris K; Di Cristofaro S; Fargnoli MC; Torlone G
    Dermatology; 1995; 190(3):214-7. PubMed ID: 7599384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional interferon therapy for basal cell carcinoma.
    Cornell RC; Greenway HT; Tucker SB; Edwards L; Ashworth S; Vance JC; Tanner DJ; Taylor EL; Smiles KA; Peets EA
    J Am Acad Dermatol; 1990 Oct; 23(4 Pt 1):694-700. PubMed ID: 2229497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of basal cell carcinoma of the nasal pyramid with intralesional interferon alfa-2b.
    Fernández-Vozmediano JM; Armario-Hita JC
    J Drugs Dermatol; 2010 Apr; 9(4):381-4. PubMed ID: 20514797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of neoplastic skin lesions with intralesional interferon.
    Wickramasinghe L; Hindson TC; Wacks H
    J Am Acad Dermatol; 1989 Jan; 20(1):71-4. PubMed ID: 2913082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression.
    Buechner SA
    J Am Acad Dermatol; 1991 May; 24(5 Pt 1):731-4. PubMed ID: 1869644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of invasive squamous cell carcinomas in biopsy-proven squamous cell carcinomas in situ sent for Mohs micrographic surgery.
    Chuang GS; Lu LK; Cummins DL; Wu H; Finn D; Rogers GS; Lee D
    Dermatol Surg; 2012 Sep; 38(9):1456-60. PubMed ID: 22734860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical comparison of p16 expression in actinic keratoses and squamous cell carcinomas of the skin.
    Hodges A; Smoller BR
    Mod Pathol; 2002 Nov; 15(11):1121-5. PubMed ID: 12429789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of topical interferon alpha 2b on actinic keratoses.
    Edwards L; Levine N; Smiles KA
    J Dermatol Surg Oncol; 1990 May; 16(5):446-9. PubMed ID: 2341658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery.
    Stenquist B; Wennberg AM; Gisslén H; Larkö O
    J Am Acad Dermatol; 1992 Jul; 27(1):65-9. PubMed ID: 1619079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Study of Treatment of Squamous Cell Carcinoma In situ.
    Övermark M; Koskenmies S; Pitkänen S
    Acta Derm Venereol; 2016 Jan; 96(1):64-7. PubMed ID: 26073523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intralesional treatment of classical Kaposi sarcoma with interferon-alpha].
    Hauschild A; Petres-Dunsche C
    Hautarzt; 1992 Dec; 43(12):789-91. PubMed ID: 1361927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma.
    Shiell A
    Australas J Dermatol; 1994; 35(2):71-5. PubMed ID: 7702490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of basal cell carcinoma with intralesional interferon alpha-2b.
    Healsmith MF; Berth-Jones J; Fletcher A; Graham-Brown RA
    J R Soc Med; 1991 Sep; 84(9):524-6. PubMed ID: 1941852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma.
    Alpsoy E; Yilmaz E; Başaran E; Yazar S
    J Dermatol; 1996 Jun; 23(6):394-6. PubMed ID: 8708151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralesional interferon-alpha 2b treatment of basal cell carcinoma.
    Thestrup-Pedersen K; Jacobsen IE; Frentz G
    Acta Derm Venereol; 1990; 70(6):512-4. PubMed ID: 1981427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional agents in the management of cutaneous malignancy: a review.
    Good LM; Miller MD; High WA
    J Am Acad Dermatol; 2011 Feb; 64(2):413-22. PubMed ID: 20334952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presentation of sebaceous carcinoma and dermatofibrosarcoma protuberans subsequent to intralesional interferon alfa-2b for the treatment of in situ squamous cell carcinoma.
    Wagner RF; Sanchez RL
    Arch Dermatol; 1991 Feb; 127(2):272. PubMed ID: 1991003
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic effect of intralesional interferon (Roferon) in squamous cell carcinoma.
    Alecu M; Ghyka G; Hălălău F; Coman G
    Rom J Intern Med; 1992; 30(3):207-10. PubMed ID: 1475599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.